

MyNorth Essentials Index Investment Options

29 September 2026



Product Disclosure Statement changes

We are updating the Product Disclosure Statement ('PDS') for investors in the MyNorth Essentials Index Investment Options ('the Investment Options') as shown below. The new PDS will be available on the website from 29 September 2026.

Investment Option	Registered name of the Fund	ARSN	APIR code	PDS & incorporated information locations (if applicable)
MyNorth Essentials Index Balanced Fund	Essentials Index Balanced Fund	677 113 316	IPA7198AU	northonline.com.au
MyNorth Essentials Index Growth Fund	Essentials Index Growth Fund	677 113 209	IPA8954AU	

The key changes include, but are not limited to:

- Updated disclosure of fees and costs

Full details of the changes can be found in the PDS. As always, we recommend you read this document to understand the main benefits and risks of investing, along with other features of the Investment Options. Indirect investors should also consider the Target Market Determination (TMD) for an Investment Option before making an investment decision, to consider whether an Investment Option is appropriate for them. TMDs in respect of the Investment Options are available at amp.com.au/investments-tmd.

Updated disclosure of fees and costs

While there have been no changes to the fee structure that applies to the Investment Options, our estimates of certain fees and costs have been updated following our latest review to ensure they accurately reflect the costs of managing the Investment Options. Full details can be found in the PDS.

Is any action required by investors?

No action is required by investors.

We're here to help

If you have any questions about this update, please contact your Client Account Manager or our Investor Services Team via email at ampinvestments@amp.com.au or on 133 267, between 8.30am and 5.30pm (Sydney time) Monday to Friday.

Yours sincerely,



Anna Hill

Head of Products & Clients
AMP Investments

On behalf of the responsible entity of the Investment Options, ipac Asset Management Limited (ABN 22 003 257 225, AFSL 234655).

Important Notice: ipac Asset Management Limited (ABN 22 003 257 225, AFSL 234655) (IAML) is the responsible entity of the MyNorth Essentials Index Investment Options ('the Investment Options') and is the issuer of the units in the Investment Options. To invest in the Investment Options, investors will need to obtain the current Product Disclosure Statement (PDS) or other offer document for the relevant Investment Options from National Mutual Funds Management Ltd (ABN 32 006 787 720, AFSL 234652) (NMFM). The PDS or offer document contains important information about investing in the Investment Options and it is important that investors read the PDS or offer document before making a decision about whether to acquire, or continue to hold or dispose of units in the Investment Options. A target market determination has been made in respect of the Investment Options and is available at amp.com.au/investments-tmd. Neither NMFM, IAML nor any other company in the AMP Group guarantees the repayment of capital or the performance of any product or any particular rate of return referred to in this document. Past performance is not a reliable indicator of future performance. Investors should consider reading the PDS for the Investment Options before making a decision regarding the Investment Options. While every care has been taken in the preparation of this document, NMFM makes no representation or warranty as to the accuracy or completeness of any statement in it including without limitation, any forecasts. This communication has been prepared for the purpose of providing general information, without taking account of any particular investor's objectives, financial situation or needs. Investors should, before making any investment decisions, consider the appropriateness of the information in this communication, and seek professional advice, having regard to their objectives, financial situation and needs. This document is solely for the use of the party to whom it is provided and must not be provided to any other person or entity without the express written consent of NMFM.